Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

FDA grants accelerated approval to Tepmetko for metastatic NSCLC with METex14 skipping alterations

Feb. 4, 2021

Erlotinib plus anlotinib shows promise in EGFR-mutated NSCLC

Feb. 4, 2021

ABTL-0812 plus paclitaxel and carboplatin result in increased efficacy in NSCLC

Feb. 4, 2021

RCC-33 reduces tumor volume in mice inoculated with colorectal cancer cells

Feb. 4, 2021

Phase Ib data show lack of objective response for CMP-001 plus atezolizumab in NSCLC

Feb. 4, 2021

Novartis discovers AKR1C3-dependent GTPase KRAS inhibitors

Feb. 4, 2021

Cybrexa 3 patents peptide conjugates of microtubule-targeting agents

Feb. 4, 2021

New cannabinoid CB1 and CB2 receptor ligands identified at Canopy Growth Corp.

Feb. 4, 2021

DexTech expands preclinical program to evaluate OsteoDex in multiple myeloma

Feb. 3, 2021

Curis initiates phase II LUCAS study of CA-4948 as treatment for anemia in MDS

Feb. 3, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...